Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -15.30
- Piotroski Score 2.00
- Grade Buy
- Symbol (LSTA)
- Company Lisata Therapeutics, Inc.
- Price $2.97
- Changes Percentage (2.07%)
- Change $0.06
- Day Low $2.93
- Day High $3.08
- Year High $3.83
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 10/28/2013
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 10/30/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.46
- Trailing P/E Ratio -1.33
- Forward P/E Ratio -1.33
- P/E Growth -1.33
- Net Income $-20,840,000
Income Statement
Quarterly
Annual
Latest News of LSTA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
A Veteran Falstaff Looks Back, and Ahead
Ambrogio Maestri, renowned bass-baritone, embodies Verdi's "Falstaff" as a second skin, having performed the role over 400 times. His recent shows at the Paris Opera and upcoming performances in Milan...
By The New York Times | 18 hours ago -
Globalstar, Inc. (GSAT): The Best Multibagger Penny Stock of 2025?
Globalstar, Inc. (PINK:GSAT) is a communication services company showing potential as a multibagger penny stock for 2025. With steady revenue growth and positive analyst outlook, GSAT ranks 3rd on the...
By Yahoo! Finance | 4 weeks ago -
Reasons to Invest in The Allstate Corporation (ALL)
Ariel Investments' second-quarter 2024 investor letter reported a -3.12% return for the Ariel Global Fund, underperforming its benchmarks. The fund focuses on undervalued franchises....
By Yahoo! Finance | 1 month ago
